Small Cell Lung Cancer
Small Cell Lung Cancer
Advertisement
Cecilia BrownASCO 2025 | June 2, 2025
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
Stephen V. Liu, MDConference Coverage | June 1, 2025
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Cecilia BrownSmall Cell Lung Cancer | June 1, 2025
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
Cecilia BrownSmall Cell Lung Cancer | April 14, 2025
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
Cecilia BrownELCC 2025 | April 4, 2025
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Cecilia BrownSmall Cell Lung Cancer | March 5, 2025
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
Jorge Nieva, MDWCLC 2024 | February 24, 2025
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MDSTS 2025 | February 14, 2025
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
Cecilia BrownSmall Cell Lung Cancer | February 6, 2025
The recommendation is based on results from the phase 3 ADRIATIC trial.
Cecilia BrownLung Cancer | January 7, 2025
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
Cecilia BrownNon-Small Cell Lung Cancer | January 6, 2025
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Cecilia BrownSmall Cell Lung Cancer | January 3, 2025
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
Cecilia BrownNon-Small Cell Lung Cancer | December 30, 2024
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Cecilia BrownSmall Cell Lung Cancer | December 20, 2024
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
Cecilia BrownSmall Cell Lung Cancer | December 20, 2024
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
Cecilia BrownSmall Cell Lung Cancer | December 17, 2024
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Cecilia BrownSmall Cell Lung Cancer | December 5, 2024
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
Laura LitwinSmall Cell Lung Cancer | November 21, 2024
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.
Yixian Chen, PhDWCLC 2024 | February 28, 2025
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Matthew Smeltzer, PhDWCLC 2024 | February 28, 2025
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Advertisement